JP2010525023A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525023A5
JP2010525023A5 JP2010504682A JP2010504682A JP2010525023A5 JP 2010525023 A5 JP2010525023 A5 JP 2010525023A5 JP 2010504682 A JP2010504682 A JP 2010504682A JP 2010504682 A JP2010504682 A JP 2010504682A JP 2010525023 A5 JP2010525023 A5 JP 2010525023A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
hydrogen
hydroxy
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525023A (ja
JP5379787B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/054977 external-priority patent/WO2008129071A1/en
Publication of JP2010525023A publication Critical patent/JP2010525023A/ja
Publication of JP2010525023A5 publication Critical patent/JP2010525023A5/ja
Application granted granted Critical
Publication of JP5379787B2 publication Critical patent/JP5379787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504682A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤 Expired - Fee Related JP5379787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2007003603 2007-04-24
EPPCT/EP2007/003603 2007-04-24
PCT/EP2008/054977 WO2008129071A1 (en) 2007-04-24 2008-04-24 Inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525023A JP2010525023A (ja) 2010-07-22
JP2010525023A5 true JP2010525023A5 (enExample) 2011-06-16
JP5379787B2 JP5379787B2 (ja) 2013-12-25

Family

ID=39529321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504682A Expired - Fee Related JP5379787B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤

Country Status (3)

Country Link
US (2) US8841315B2 (enExample)
JP (1) JP5379787B2 (enExample)
WO (1) WO2008129071A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9093366B2 (en) 2012-04-09 2015-07-28 Transphorm Inc. N-polar III-nitride transistors

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079345A1 (en) * 2010-03-22 2013-03-28 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH スルホキシイミン基を含有する二置換5−フルオロピリミジン誘導体
EP2755956B1 (en) 2011-09-16 2016-05-18 Bayer Intellectual Property GmbH 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
US8598937B2 (en) 2011-10-07 2013-12-03 Transphorm Inc. High power semiconductor electronic components with increased reliability
US8803246B2 (en) 2012-07-16 2014-08-12 Transphorm Inc. Semiconductor electronic components with integrated current limiters
CA2888383A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
WO2014060375A2 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
US9087718B2 (en) 2013-03-13 2015-07-21 Transphorm Inc. Enhancement-mode III-nitride devices
US9245993B2 (en) 2013-03-15 2016-01-26 Transphorm Inc. Carbon doping semiconductor devices
EP3016945B1 (en) 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9443938B2 (en) 2013-07-19 2016-09-13 Transphorm Inc. III-nitride transistor including a p-type depleting layer
WO2015136028A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
WO2015155197A1 (en) 2014-04-11 2015-10-15 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
US9543940B2 (en) 2014-07-03 2017-01-10 Transphorm Inc. Switching circuits having ferrite beads
US9318593B2 (en) 2014-07-21 2016-04-19 Transphorm Inc. Forming enhancement mode III-nitride devices
WO2016059011A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
CA2964696C (en) 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
CA2980507A1 (en) 2015-03-24 2016-09-29 Public University Corporation Nagoya City University Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
CA2980493A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
ES2728356T3 (es) 2015-06-29 2019-10-23 Astrazeneca Ab Derivados de amidas policíclicas como inhibidores de CDK9
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP6888013B2 (ja) 2016-01-15 2021-06-16 トランスフォーム テクノロジー,インコーポレーテッド AL(1−x)Si(x)Oゲート絶縁体を有するエンハンスメントモードIII族窒化物デバイス
WO2017210323A1 (en) 2016-05-31 2017-12-07 Transphorm Inc. Iii-nitride devices including a graded depleting layer
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
MX2020008447A (es) 2018-02-13 2020-09-28 Bayer Ag Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimi doil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de celulas grandes b.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2-取代的4-杂芳基-嘧啶、其组合物及其用途
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9093366B2 (en) 2012-04-09 2015-07-28 Transphorm Inc. N-polar III-nitride transistors

Similar Documents

Publication Publication Date Title
JP2010525023A5 (enExample)
JP2011502956A5 (enExample)
JP2017502940A5 (enExample)
RU2012143897A (ru) Замещенные пиримидины как антагонисты рецепторов простагландина d2
JP2010525025A5 (enExample)
JP2016520131A5 (enExample)
JP2021512150A5 (enExample)
JP2011137006A5 (enExample)
JP2013509431A5 (enExample)
JP2007534695A5 (enExample)
JP2013528204A5 (enExample)
JP2013510125A5 (enExample)
JP2009533410A5 (enExample)
JP2016506958A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2015517579A5 (enExample)
JP2004536814A5 (enExample)
JP2013510124A5 (enExample)
JP2016532673A5 (enExample)
JP2011519854A5 (enExample)
JP2014507464A5 (enExample)
JP2022505645A5 (enExample)
JP2013544860A5 (enExample)
JP2016505021A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents